David Lubner
Board Member
Crescent Biopharma, Inc. (CBIO)Equibles does not estimate personal net worth.
Get an email with a short summary when Crescent Biopharma, Inc. publishes a filing, an earnings call transcript or a press release.
Get CBIO alertsAbout David Lubner
David Lubner is recorded as Board Member at Crescent Biopharma, Inc. (CBIO). The newest filing on record that lists David Lubner as Board Member at Crescent Biopharma, Inc. (CBIO) is dated April 21, 2026. Earlier roles on record: Board Member at Disc Medicine, Inc. (IRON) until December 29, 2022 and Board Member at Arcellx, Inc. until April 28, 2026. Vor Biopharma Inc. reported in an 8-K filed August 27, 2025 that David Lubner resigned as Director, effective August 26, 2025. Crescent Biopharma, Inc. reported in an 8-K filed July 31, 2025 that David Lubner was appointed board of directors. Crescent Biopharma, Inc. reported in an 8-K filed June 18, 2025 that David Lubner was appointed director, effective June 13, 2025. Equibles holds 4 filed executive changes naming David Lubner; each is listed under recent activity with its source filing. Crescent Biopharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Crescent Biopharma, Inc. includes Joshua Brumm (CEO and Board Member), Peter Harwin (Chairman and Board Member), Richard Scalzo (CFO) and 7 others.
“On August 26, 2025, David Lubner, a member of the Board, delivered his notice of resignation to the Board, effective immediately.”
“The Company appointed David Lubner to Crescent's board of directors.”
Affiliation history
-
Current
Start not stated–present
Last confirmed April 21, 2026
-
2021-02-05–2022-12-29
-
Arcellx, Inc.
Board Member
Proxy statement
2020-01-01–2026-04-28
-
2020-01-01–2022-12-29
Company network
Arcellx, Inc.
Biotechnology · Healthcare
Board Member
2020-01-01–2026-04-28
Leadership on record at Crescent Biopharma, Inc.
- Joshua Brumm CEO, Board Member
- Peter Harwin Chairman, Board Member
- Richard Scalzo CFO
- Rick Scalzo CFO
- Jonathan McNeill COO
- Barbara Bispham General Counsel
- Barbara Bispham Hale General Counsel
- Ryan Lynch Chief Accounting Officer
- Alexandra Balcom Board Member
- Jonathan Violin Board Member